Graphical Abstract Biocatalyzed synthesis of difuranosides and their ability to trigger production of TNF-D D Biocatalyzed synthesis of difuranosides and their ability to trigger production of TNF-D D by Chlubnová, Ilona et al.
Graphical Abstract Biocatalyzed synthesis of
difuranosides and their ability to trigger production of
TNF-D D Biocatalyzed synthesis of difuranosides and
their ability to trigger production of TNF-D D
Ilona Chlubnova´, Blanka Kra´lova´, Hana Dvorˇa´kova´, Vojteˇch Spiwok, Dominik
Filipp, Caroline Nugier-Chauvin, Richard Daniellou, Vincent Ferrie`res
To cite this version:
Ilona Chlubnova´, Blanka Kra´lova´, Hana Dvorˇa´kova´, Vojteˇch Spiwok, Dominik Filipp, et al..
Graphical Abstract Biocatalyzed synthesis of difuranosides and their ability to trigger pro-
duction of TNF-D D Biocatalyzed synthesis of difuranosides and their ability to trigger pro-
duction of TNF-D D. Bioorganic and Medicinal Chemistry Letters, Elsevier, 2016, In press.
<10.1016/j.bmcl.2016.02.018>. <hal-01272616>
HAL Id: hal-01272616
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01272616
Submitted on 11 Feb 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Graphical Abstract 
Biocatalyzed synthesis of difuranosides and 
their ability to trigger production of TNF-? 
Ilona Chlubnová, Blanka Králová, Hana Dvořáková, Vojtěch Spiwok, Dominik Filipp, Caroline Nugier-
Chauvin, Richard Daniellou and Vincent Ferrières 
  
Biocatalyzed synthesis of difuranosides and their ability to trigger production of 
TNF-? 
Ilona Chlubnováa,b,c,e, Blanka Králová*,a,c, Hana Dvořákovác,d, Vojtěch Spiwokc, Dominik Filippe, Caroline 
Nugier-Chauvina,b, Richard Danielloua,b,§ and Vincent Ferrières?a,b 
a Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France 
b Université européenne de Bretagne, France 
c Department of Biochemistry and Microbiology, Institute of Chemical Technology of Prague, Techniká 3, 166 28 Prague 6 (Czech Republic) 
d Laboratory of NMR spectroscopy, Institute of Chemical Technology of Prague, Techniká 5, 166 28 Prague 6 (Czech Republic) 
e Laboratory of Immunobiology, Institute of Molecular Genetics AS CR, Videnska 1083, 142 20 Prague 4 (Czech Republic) 
——— 
§ Present address: Institut de Chimie Organique et Analytique (ICOA), UMR CNRS 7311, Université d’Orléans, BP 6759, Rue de Chartres,
45067 Orléans Cedex 2, France 
? Corresponding author: Vincent Ferrières. Tel.: +33-223-238-058; e-mail: vincent.ferrieres@ensc-rennes.fr 
1. Introduction
Rare hexofuranosides occur in many microorganisms but are
absent from the mammalian kingdom and invertebrates. That is 
why they constitute nowadays a source of inspiration to develop 
new treatments to fight pathogenic microorganisms for which the 
biosynthesis of these carbohydrates is vital.1-4.Indeed, 
immunological, antiviral and antiparasitic properties of 
furanosyl-containing compounds are increasingly evidenced.5-
13.In this context, many efforts have been investigated to prepare 
and to mimic glycofuranoconjugates by both conventional 
chemical approaches and original enzymatic tools. Considering 
the latter, two classes of biocatalysts can be exploited. The 
usefulness of furanosyl transferases is dampened by its limited 
access to both these enzymes as well as the required UDP- or 
polyprenyl-furanosyl donors. On another hand, glycosyl 
hydrolases are more easily available and robust, therefore are 
more interesting as alternative synthetic tools, provided they are 
used under kinetic conditions, i.e. as a synthetic catalyst and not 
as a hydrolytic one. Surprisingly, reported results in this domain 
focused on only two arabinofuranosidases: AbfD3 produced by 
Thermocellum xylanilyticus,14-17.and an enzyme exploited by our 
group Araf51 from Clostridium thermocellum.18-21.AbfD3 led to 
disaccharides and allowed Araf transfer to xylobiose and 
xylotriose. As for Araf51, we have demonstrated that it is 
involved in autocondensation reactions yielding di- to 
pentasaccharides. Both enzymes catalyzed the synthesis of 
furanosyl-containing glycosides starting from p-nitrophenyl L-
arabinofuranosides (pNP Araf) but also from structurally related 
D-galacto- (D-Galf) and D-fucofuranosyl (D-Fucf) series: AbfD3 
led to disaccharides and allowed Araf transfer to xylobiose and 
xylotriose, while Araf51 was involved in the transfer of di- to 
pentasaccharides in autocondensation reactions. 
The higher synthetic potential of native Araf51 was 
demonstrated for autocondensation reactions20.and in 
transglycosylation with pyranosidic acceptors.21.Herein, this 
potency was applied in transglycosylation involving two 
furanosidic substrates, D-galactofuranosyl donor and various 
furanosidic acceptors [D-Galf, D-Fucf, 6-deoxy-6-fluoro-D-
galactofuranoside (6-F-D-Galf), Figure 1]. The choice of D-Galf 
as the donor was based on its occurrence in glycoconjugates of 
numerous pathogenic species.22, 23.As for the furanosidic 
acceptors, we examined the ability of the enzyme to accept 
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Transglycosylation reactions biocatalyzed by the native arabinofuranosidase Araf51 and using D-galactosyl, D-fucosyl and 
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structural analogues of β-D-Galf in the +I-subsite as well as the 
possible effect on the enzyme regioselectivity in the absence of a 
hydroxyl function on C-6 of the acceptor. Regarding the enzyme 
preferences toward formation of the (1→6) linkage in β-D-Galf 
series, we were interested in the effect of restriction of C-6 
participation in the bond formation. To this end, β-D-Galf moiety 
was modified at C-6 by the replacement of the hydroxyl group 
with either hydrogen (β-D-Fucf), or fluorine (6-F-β-D-Galf). 
Moreover, the set of furanosidic acceptors were also represented 
by an octyl group at the anomeric position. First, we anticipated 
that the alkoxyl chain is a more inferior leaving group in 
comparison to the nitrophenolate, hence octyl furanosides would 
mainly play the role of acceptors. Second, numerous studies have 
highlighted the importance of alkyl chains in various biological 
activities.7, 24-26.Using alkyl furanosides as acceptors will 
therefore allow the direct synthesis of glycolipidomimetics. 
Finally, immunological properties of the neo-oligofuranosides 
will be assessed, with a particular focus on the expression of 
tumor necrosis factor-? (TNF-?). 
 
 
Transglycosylation was first performed with Oct β-D-Galf as 
the acceptor (Table 1, family A). Using size exclusion 
chromatographic purification, fractions of disaccharides (entries 
1 and 2, 45%), trisaccharides (entries 3 and 4, 18%), 
tetrasaccharides (entry 5, 2%), and pentasaccharides (entry 6, 
1%) were obtained. As expected, autocondensation of the donor 
pNP β-D-Galf proceeded simultaneously resulting in a 34% yield 
of pNP glycosides. After 90 minutes, the conversion of pNP β-D-
Galf was nearly complete with only 4% of the donor remaining. 
While the donor molecule was nearly entirely consumed, only 
55% of acceptor Oct β-D-Galf was transformed. The detailed 
molar balance of reaction products clearly indicates that the 
acceptor Oct β-D-Galf simultaneously acted as a donor. Overall, 
an octyl aglycon initially intended as a protecting group turned 
out to be a good leaving group in the Araf51-mediated 
transglycosylation. The nature of the superior nucleofugality of 
the p-nitrophenate group versus the octanolate anion has shown 
not to be determinant enough. Besides tryptophan residue in the 
+I-subsite of Araf51 (Trp178) forming a hydrophobic stacking 
with an acceptor, the funnel of the +I-subsite is furnished with a 
number of other aromatic/hydrophobic residues27.which could 
provide a complementary environment, facilitating the leaving of 
the alkoxyl chain. 
Next, transglycosylation was performed in the presence of Oct 
β-D-Fucf. After purification, mainly di- and trisaccharides were 
isolated at 20% (Table 1, entries 7-9, family B) and 11% yields 
(entries 10-12), respectively. It is noteworthy that (i) the 
conversion of pNP β-D-Galf in the presence of Oct β-D-Fucf 
proceeded much slower than in the case of Oct β-D-Galf (48% vs. 
96 % after 90 min), (ii) the conversion of Oct β-D-Fucf (42%) 
was comparable to that of the donor pNP β-D-Galf, in contrast to 
the transglycosylation reaction with Oct Galf as acceptor, (iii) the 
degree of hydrolysis was very low, with a yield of less than 3% 
of the products. Therefore, these observations indicate that the 
presence of Oct β-D-Fucf reduces pNP β-D-Galf 
autocondensation. Because of the low solubility of Oct β-D-Fucf 
in water, the corresponding kinetic parameters could not be 
determined. Nevertheless, we hypothesized that the acceptor Oct 
β-D-Fucf is significantly retained within the donor –I-subsite, 
thus limiting the access of the donor pNP β-D-Galf. To 
corroborate this hypothesis, analysis of isolated products revealed 
the presence of a fucosyl residue at the non-reducing end of a 
number of resulting saccharides. This clearly demonstrated that 
Araf51 is able to use Oct β-D-Fucf simultaneously and efficiently 
as a donor and an acceptor. 
Finally, transglycosylation with Oct 6-F-β-D-Galf (entries 15-
18, family C) as the acceptor was characterized by the slow rate 
of the reaction: (i) conversion of pNP β-D-Galf reached only 43% 
after 90 minutes and (ii) Oct 6-F-β-D-Galf was barely converted 
to the reaction products; its consumption did not exceed 20%. 
Nevertheless, there was a very low degree of hydrolysis (2%), 
and similarly to the reaction with Oct β-D-Fucf, pNP β-D-Galf 
acted as a better acceptor than Oct 6-F-β-D-Galf. It is interesting 
to note that pNP β-D-Galf residue was more frequently found in 
the reducing position of products. Taking together the very low 
degree of hydrolysis and pNP β-D-Galf autocondensation as well 
as the unwillingness of Oct 6-F-β-D-Galf to participate in the 
formation of transglycosylation products, this implies that the 
presence of fluorine has an inhibitory effect on enzyme activity. 
It seems that 6-F-β-D-Galf residue is strongly retained in the 
donor subsite resulting in a more rapid process of the transfer of 
the β-D-Galf residue to an acceptor. 
Table 1. Oligofuranosides produced with Araf51. 
Entry R Oligosaccharides (Yield) 
1 OH Adi1 Galf-Galf-OpNP (26%) 
2 (Oct ?-D-Galf) Adi2 Galf-Galf-OC8H17 (19%) 
3 Atri1 Galf-Galf- Galf-OpNP (8%) 
4 Atri2 Galf-Galf- Galf-OC8H17 (9%) 
5 Atetra Galf-Galf- Galf- Galf-OC8H17 (2%) 
6 Apenta Galf-Galf- Galf- Galf-Galf-OC8H17 
(1%) 
7 H Bdi1 Fucf-Galf-OpNP (12%) 
8 (Oct ?-D-Fucf) Bdi2 Fucf-Fucf-OC8H17 (4%) 
9 Bdi3 Galf-Fucf- OC8H17 (4%) 
10 Btri1 Fucf-Fucf-Galf-OpNP (5%) 
11 Btri2 Fucf-Galf-Galf-OpNP or Galf-Fucf-
Galf-OpNP (5%) 
12 Btri3 Galf- Galf- Fucf-OC8H17 (1%) 
13 F Cdi1 Galf- Galf-OpNP (13%) 
14 (Oct Cdi2 6-F-Galf- Galf-OpNP (3%) 
15 6-F-?-D-Galf) Cdi3 Galf-6-F-Galf-OC8H17 (6%) 
16 Cdi4 6-F-Galf-6-F-Galf-OC8H17 (3%) 
17 Ctri1 6-F-Galf-Galf-Galf-OpNP or Galf-6-
F-Galf- Galf-OpNP (1%) 
18 Ctri2 Galf-Galf-6-F-Galf-OC8H17 (1%) 
Further chromatographic separation led to disaccharides 1-11 
(Figure 2) which were identified by mass spectrometry and their 
structures elucidated by 1D and 2D NMR. The ?-configuration of 
the newly formed furanosidic linkages were based on a small H1-
Figure 1. Structures of furanosyl donor and acceptors for biocatalyzed 
transglycosylation reactions. 
H2 coupling constant less than 1.0 Hz. The five-membered ring 
size of the transferred glycosyl entity was deduced from the latter 
value, which is specific to furanosides,28.and from 13C NMR data, 
i.e. 107.4 ppm for C1, a value that also corroborates the ?-
configuration, and a chemical shift upper to 80 ppm for C-
4.29.Finally, the regioselectivity of the glycosidic coupling was 
established by comparing the chemical shifts of the carbon atoms 
of the reducing entity with those of the starting acceptor since O-
glycosylation results in downfield chemical shifts.29.For instance, 
?C2a increased from 81.6 ppm to 87.5 ppm in compound 1 while ?C6a rose 6.2 ppm (from 62.9 ppm to 69.1 ppm) in disaccharide 2. 
For disaccharides 4 and 10, downfield chemical shifts from 76.6 
ppm to 82.3 ppm, and from 62.8 ppm to 69.1 ppm, corroborated 
(1→3) and (1→6) new glycosidic linkages, respectively. 
 
To evaluate the immunomodulatory potency of enzymatically 
synthesized neofuranosides, these molecules were incubated with 
the murine macrophage cell line, Raw 264.7. All glycoconjugates 
were tested at concentrations of 1, 10, 100 and 1000 ng/mL. E. 
coli lipopolysaccharide (LPS) was used as a positive control. 
After 18 hours of incubation, the production of tumor necrosis 
factor-? (TNF-?) in the culture medium was assessed using 
TNF-?-specific ELISA. While in the unstimulated control 
sample, Raw 264.7 secreted only background levels of TNF-? 
(4.4 ± 3.4 pg/mL, not shown), these levels in positive control 
samples stimulated with 100 ng/mL of LPS reached 880 ± 53 
pg/mL. Importantly, significant TNF-? responses (up to 800 
pg/mL) were elicited upon stimulation with the indicated 
oligofuranosides when used at concentrations of 100 and 1000 
ng/mL (Figure 3). It is of note that only trace and non-stimulatory 
levels of LPS were detected in the samples used, as admixing 
LPS inhibitor polymyxin B to cell cultures resulted in the 
production of comparable levels of TNF-? (data not shown). 
TNF-? protein levels produced by regioisomers of 
galactofuranosides (A) and their structural analogues 
fucofuranosides (B) or 6-deoxy-6-fluorogalactofuranosides (C) 
clearly demonstrated that certain structural features play an 
important role in their bioactivity. First, as depicted in figure 3, 
oligofuranosides bearing a pNP aglycon exhibited a weaker 
effect on TNF-? production than that induced by octyl 
oligosaccharides, provided that the number of glycosyl units was 
equivalent. Nevertheless, oligofuranosides from families A (Galf) 
and C (Galf, 6-F-Galf) are better inducers of the production of 
target cytokine than those of family B (Galf, Fucf). Second, 
although more noticeable with the octyl series, the length of the 
carbohydrate chain was of great importance since biological 
activity significantly increased with the number of furanosyl 
rings, irrespectively to the nature of the glycosyl units (Galf, 
Fucf, or 6-F-Galf). This chain length-dependent activity has been 
previously described with synthetic
oligoarabinofurnaosides.20.Third, fluorine-containing di- or 
trisaccharides C seem to be much more efficient than their 
hydroxylated or deoxy counterparts. Indeed, the disaccharide 11 
displayed a similar biological effect than the tested 
pentasaccharide (TNF-?>200 pg/mL), which represents 
approximately 2.5-times greater immunostimulatory potential. 
While it is difficult to predict the impact of the number of 
fluorine atoms as well as the position of fluorinated units along 
the octyl oligofuranoside on the biological activity, adding a 
furanosidic unit can significantly increase the production of TNF-
? which reached 600 pg/mL for the fraction 6-F-Galf-6-F-Galf-
OC8H17. 
To conclude, a set of original oligofuranosides which are 
structurally-related to D-galactofuranose and possess chemical 
modulations on the primary position was obtained using native 
type Araf51. This biocatalyst allowed the synthesis of D-Galf 
derivatives but also oligomers derived from D-fucofuranose and 
6-deoxy-6-fluoro-D-galactofuranose. In each case, the 
transglycosylation process constituted a major reaction with a 
very low degree of hydrolysis. Importantly, the octyl furanosides 
first designed as acceptors also played the role of donors, 
probably thanks to a good recognition within the –I sub-site. All 
of the compounds were tested on Raw264.7 cells in order to 
evaluate their immunostimulatory activity. They significantly 
upregulate TNF-? secretion in a concentration-, chain length- 
Figure 2. Elucidated structures of isolated difuranosides.
and aglycon-dependent fashion. Importantly, the presence of an 
alkyl chain and/or of fluorine atoms significantly increased 
biological activity. Consequently, both arabinofuranosyl and 
galactofuranosyl derivatives are compounds of interest for their 
immunostimulatory properties and further studies are currently 
underway to evaluate their potential as adjuvants in vaccine 
development. 
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